
Nicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.

Your AI-Trained Oncology Knowledge Connection!


Nicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.

Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.

An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.

Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.

Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.

The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.

Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.

Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.

An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.

Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.

Published: March 28th 2022 | Updated:

Published: February 9th 2021 | Updated:

Published: February 9th 2021 | Updated:

Published: February 9th 2021 | Updated:

Published: February 9th 2021 | Updated:

Published: February 9th 2021 | Updated: